Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

PRAVEEN KUMAR TUMULA

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1447402896
CMS profile
746364
Location
AMARILLO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$1,168.66

28 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $561.47 24
Consulting Fee $500.00 2
Education $107.19 2

By paying entity

PY2019 · entire year · sorted by reported total

Page 1 of 1; records 1–28 of 28 matching records. This page contains 28 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

PRAVEEN KUMAR TUMULA

NPI 1447402896 · CMS profile ID 746364

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

AMARILLO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–28 of 28 matching records. This page contains 28 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1447402896?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
PRAVEEN KUMAR TUMULA, NPI 1447402896, CMS profile ID 746364. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–28 of 28 matching records. This page contains 28 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1447402896?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). PRAVEEN KUMAR TUMULA, NPI 1447402896, CMS profile ID 746364. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–28 of 28 matching records. This page contains 28 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1447402896?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
PRAVEEN KUMAR TUMULA, NPI 1447402896, CMS profile ID 746364, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–28 of 28 matching records. This page contains 28 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1447402896?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

28 matching records · $1,168.66 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 28 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–28 of 28.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
JAZZ PHARMACEUTICALS INC. $13.7311/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684185893 CMS
E.R. Squibb & Sons, L.L.C. $5.1411/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651387417 CMS
E.R. Squibb & Sons, L.L.C. $250.0011/12/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651387419 CMS
Seattle Genetics, Inc. $12.2110/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 678807669 CMS
Kite Pharma, Inc. $13.6710/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662138541 CMS
Celgene Corporation $20.6909/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672928045 CMS
Clovis Oncology, Inc. $7.2009/18/2019 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688684447 CMS
Incyte Corporation $11.8409/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 666278771 CMS
Merck Sharp & Dohme Corporation $65.7309/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695746359 CMS
Incyte Corporation $13.3208/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 666278765 CMS
TESARO, Inc. $11.3607/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 675571281 CMS
Takeda Pharmaceuticals U.S.A., Inc. $125.0007/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697395577 CMS
Genentech USA, Inc. $16.2305/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681278233 CMS
Seattle Genetics, Inc. $72.3305/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 678807659 CMS
TESARO, Inc. $14.6605/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 675571279 CMS
Astellas Pharma US Inc $99.9905/02/2019 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 655784729 CMS
E.R. Squibb & Sons, L.L.C. $250.0004/22/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651387429 CMS
Janssen Pharmaceuticals, Inc $15.2904/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659349041 CMS
E.R. Squibb & Sons, L.L.C. $11.5904/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651387365 CMS
Takeda Pharmaceuticals U.S.A., Inc. $9.4303/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 696702587 CMS
E.R. Squibb & Sons, L.L.C. $9.1502/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651387369 CMS
AbbVie, Inc. $18.9602/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648247317 CMS
Astellas Pharma US Inc $12.5802/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 655784725 CMS
Janssen Scientific Affairs, LLC $37.1201/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657610129 CMS
Merck Sharp & Dohme Corporation $20.7401/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695651798 CMS
PFIZER INC. $11.1001/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671856639 CMS
Takeda Pharmaceuticals U.S.A., Inc. $15.6201/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697381769 CMS
E.R. Squibb & Sons, L.L.C. $3.9801/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651387367 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,168.66 28
PY2020 $4,815.65 8
PY2021 $340.16 6
PY2022 $1,916.32 26
PY2023 $4,540.57 16
PY2024 $2,679.61 6
PY2025 $6,258.84 11

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $604,557.82 36
PY2024 Principal investigator $1,085,444.24 161
PY2023 Principal investigator $684,815.25 77
PY2022 Principal investigator $638,195.90 127
PY2021 Principal investigator $416,830.90 164
PY2020 Principal investigator $201,522.62 122
PY2019 Recipient $1,287.72 1
PY2019 Principal investigator $54,363.67 98

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

164 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Incyte Corporation $120.00 12/22/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 831123159
Principal investigator 1 Incyte Corporation $120.00 12/22/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 831123169
Principal investigator 1 BeiGene, Ltd. $37,600.00 12/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY-ARLINGTON SOUTH
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Intolerant of Prior Treatment with Ibrutinib No dispute reported 06/30/2026 843879577
Principal investigator 1 Incyte Corporation $489.00 12/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 831123383
Principal investigator 1 Incyte Corporation $105.00 12/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 831123391
Principal investigator 1 Incyte Corporation $489.00 12/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 831123567
Principal investigator 1 Incyte Corporation $489.00 12/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 831123577
Principal investigator 1 Incyte Corporation $489.00 12/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 831123587
Principal investigator 1 Incyte Corporation $105.00 12/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 831123597
Principal investigator 1 Incyte Corporation $489.00 12/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 831123607
Principal investigator 1 Pharmacyclics LLC, an AbbVie Company $190.00 12/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) No dispute reported 06/30/2026 786502767
Principal investigator 1 Incyte Corporation $120.00 11/18/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 831123073
Principal investigator 1 Incyte Corporation $106.00 11/18/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 831123081
Principal investigator 1 Incyte Corporation $105.00 11/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 831123361
Principal investigator 1 Incyte Corporation $489.00 11/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 831123373
Principal investigator 1 Incyte Corporation $105.00 11/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 831123511
Principal investigator 1 Incyte Corporation $489.00 11/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 831123521
Principal investigator 1 Incyte Corporation $105.00 11/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 831123529
Principal investigator 1 Incyte Corporation $489.00 11/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 831123537
Principal investigator 1 Incyte Corporation $489.00 11/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 831123549
Principal investigator 1 Incyte Corporation $489.00 11/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 831123559
Principal investigator 1 BeiGene, Ltd. $9,400.00 11/08/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY-ARLINGTON SOUTH
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Intolerant of Prior Treatment with Ibrutinib No dispute reported 06/30/2026 843877251
Principal investigator 1 Incyte Corporation $240.00 10/28/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 831122897
Principal investigator 1 Incyte Corporation $636.00 10/21/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 831122877
Principal investigator 1 Genentech, Inc. $2,550.00 10/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY SOUTHWEST FORT WORTH
CLL 1L FIT GV FCR BR No dispute reported 06/30/2026 836026657
Principal investigator 1 Incyte Corporation $850.00 10/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 831123351
Principal investigator 1 Pharmacyclics LLC, an AbbVie Company $638.00 10/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) No dispute reported 06/30/2026 786502765
Principal investigator 1 Seagen Inc. $956.00 10/15/2021 Non-covered Recipient Entity
Texas Oncology-Amarillo
A Dual-cohort, Open-label, Phase 2 Study of Brentuximab Vedotin and CHP (A+CHP) in the Frontline Treatment of Subjects With Peripheral T-cell Lymphoma (PTCL) With Less Than 10% CD30 Expression No dispute reported 06/30/2026 792678975
Principal investigator 1 Incyte Corporation $120.00 10/14/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 831122867
Principal investigator 1 Incyte Corporation $240.00 10/07/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 831122857
Principal investigator 1 Incyte Corporation $120.00 10/07/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 831122915
Principal investigator 1 Incyte Corporation $1,000.00 10/07/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 831122965
Principal investigator 1 Incyte Corporation $240.00 09/23/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 831121577
Principal investigator 1 Incyte Corporation $106.00 09/23/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 831121633
Principal investigator 1 Incyte Corporation $212.00 09/23/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 831121641
Principal investigator 1 BeiGene, Ltd. $37,600.00 09/21/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY-ARLINGTON SOUTH
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Intolerant of Prior Treatment with Ibrutinib No dispute reported 06/30/2026 843878983
Principal investigator 1 Incyte Corporation $489.00 09/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 831121857
Principal investigator 1 Incyte Corporation $105.00 09/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 831121867
Principal investigator 1 Incyte Corporation $489.00 09/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 831122113
Principal investigator 1 Incyte Corporation $6,312.79 08/26/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 831121443
Principal investigator 1 Incyte Corporation $226.00 08/26/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 831121452
Principal investigator 1 BeiGene, Ltd. $9,400.00 08/16/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY-ARLINGTON SOUTH
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Intolerant of Prior Treatment with Ibrutinib No dispute reported 06/30/2026 843879633
Principal investigator 1 Celgene Corporation $952.00 08/15/2021 Non-covered Recipient Entity
Texas Oncology
Connect MM- The Multiple Myeloma Disease Registry No dispute reported 06/30/2026 807115635
Principal investigator 1 Celgene Corporation $476.00 08/15/2021 Non-covered Recipient Entity
Texas Oncology
Connect MM- The Multiple Myeloma Disease Registry No dispute reported 06/30/2026 807115719
Principal investigator 1 Incyte Corporation $489.00 08/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 831121839
Principal investigator 1 Incyte Corporation $105.00 08/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 831121847
Principal investigator 1 Incyte Corporation $489.00 08/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 831122105
Principal investigator 1 Pharmacyclics LLC, an AbbVie Company $190.00 08/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) No dispute reported 06/30/2026 786502757
Principal investigator 1 Pharmacyclics LLC, an AbbVie Company $190.00 08/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) No dispute reported 06/30/2026 786502759
Principal investigator 1 Pharmacyclics LLC, an AbbVie Company $190.00 08/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) No dispute reported 06/30/2026 786502761
Principal investigator 1 Pharmacyclics LLC, an AbbVie Company $190.00 08/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) No dispute reported 06/30/2026 786502763
Principal investigator 1 Incyte Corporation $105.00 07/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 831121813
Principal investigator 1 Incyte Corporation $489.00 07/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 831121821
Principal investigator 1 Incyte Corporation $850.00 07/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 831121829
Principal investigator 1 Incyte Corporation $105.00 07/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 831122075
Principal investigator 1 Incyte Corporation $489.00 07/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 831122085
Principal investigator 1 Incyte Corporation $489.00 07/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 831122095
Principal investigator 1 Pharmacyclics LLC, an AbbVie Company $190.00 07/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) No dispute reported 06/30/2026 786502741
Principal investigator 1 Pharmacyclics LLC, an AbbVie Company $190.00 07/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) No dispute reported 06/30/2026 786502743
Principal investigator 1 Pharmacyclics LLC, an AbbVie Company $190.00 07/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) No dispute reported 06/30/2026 786502745
Principal investigator 1 Pharmacyclics LLC, an AbbVie Company $190.00 07/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) No dispute reported 06/30/2026 786502747
Principal investigator 1 Pharmacyclics LLC, an AbbVie Company $190.00 07/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) No dispute reported 06/30/2026 786502749
Principal investigator 1 Pharmacyclics LLC, an AbbVie Company $190.00 07/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) No dispute reported 06/30/2026 786502751
Principal investigator 1 Pharmacyclics LLC, an AbbVie Company $190.00 07/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) No dispute reported 06/30/2026 786502753
Principal investigator 1 Pharmacyclics LLC, an AbbVie Company $638.00 07/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) No dispute reported 06/30/2026 786502755
Principal investigator 1 Seagen Inc. $6,800.00 07/15/2021 Non-covered Recipient Entity
Texas Oncology-Amarillo
A Dual-cohort, Open-label, Phase 2 Study of Brentuximab Vedotin and CHP (A+CHP) in the Frontline Treatment of Subjects With Peripheral T-cell Lymphoma (PTCL) With Less Than 10% CD30 Expression No dispute reported 06/30/2026 792678969
Principal investigator 1 Seagen Inc. $956.00 07/15/2021 Non-covered Recipient Entity
Texas Oncology-Amarillo
A Dual-cohort, Open-label, Phase 2 Study of Brentuximab Vedotin and CHP (A+CHP) in the Frontline Treatment of Subjects With Peripheral T-cell Lymphoma (PTCL) With Less Than 10% CD30 Expression No dispute reported 06/30/2026 792678977
Principal investigator 1 Genentech, Inc. $1,500.00 07/05/2021 Non-covered Recipient Entity
PHYSICIANS RELIANCE NETWORK US ONCOLOGY RESEARCH INC
CLL 1L FIT GV FCR BR No dispute reported 06/30/2026 835990813
Principal investigator 1 BeiGene, Ltd. $1,125.00 06/30/2021 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A Single-Arm, Expanded Access Study of Zanubrutinib (BGB-3111) in Patients with B-cell Malignancies No dispute reported 06/30/2026 843874715
Principal investigator 1 BeiGene, Ltd. $37,600.00 06/29/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY-ARLINGTON SOUTH
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Intolerant of Prior Treatment with Ibrutinib No dispute reported 06/30/2026 843877361
Principal investigator 1 Incyte Corporation $489.00 06/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 831120949
Principal investigator 1 Incyte Corporation $105.00 06/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 831120955
Principal investigator 1 Incyte Corporation $489.00 06/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 831121289
Principal investigator 1 Pharmacyclics LLC, an AbbVie Company $190.00 06/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) No dispute reported 06/30/2026 786502725
Principal investigator 1 Pharmacyclics LLC, an AbbVie Company $190.00 06/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) No dispute reported 06/30/2026 786502727
Principal investigator 1 Pharmacyclics LLC, an AbbVie Company $190.00 06/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) No dispute reported 06/30/2026 786502729
Principal investigator 1 Pharmacyclics LLC, an AbbVie Company $190.00 06/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) No dispute reported 06/30/2026 786502731
Principal investigator 1 Pharmacyclics LLC, an AbbVie Company $190.00 06/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) No dispute reported 06/30/2026 786502733
Principal investigator 1 Pharmacyclics LLC, an AbbVie Company $190.00 06/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) No dispute reported 06/30/2026 786502735
Principal investigator 1 Pharmacyclics LLC, an AbbVie Company $190.00 06/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) No dispute reported 06/30/2026 786502737
Principal investigator 1 Pharmacyclics LLC, an AbbVie Company $190.00 06/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) No dispute reported 06/30/2026 786502739
Principal investigator 1 BeiGene, Ltd. $47,000.00 05/25/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY-ARLINGTON SOUTH
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Intolerant of Prior Treatment with Ibrutinib No dispute reported 06/30/2026 843879113
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,287.72 05/18/2021 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A GLOBAL, PROSPECTIVE, NON-INTERVENTIONAL, OBSERVATIONAL STUDY OF PRESENTATION, TREATMENT PATTERNS, AND OUTCOMES IN MULTIPLE MYELOMA PATIENTS - THE INSIGHT - MM STUDY No dispute reported 06/30/2026 816724897
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $6,009.36 05/18/2021 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A GLOBAL, PROSPECTIVE, NON-INTERVENTIONAL, OBSERVATIONAL STUDY OF PRESENTATION, TREATMENT PATTERNS, AND OUTCOMES IN MULTIPLE MYELOMA PATIENTS - THE INSIGHT - MM STUDY No dispute reported 06/30/2026 816724955
Principal investigator 1 Incyte Corporation $105.00 05/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 831120895
Principal investigator 1 Incyte Corporation $489.00 05/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 831120901
Principal investigator 1 Incyte Corporation $105.00 05/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 831121173
Principal investigator 1 Incyte Corporation $489.00 05/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 831121179
Principal investigator 1 Incyte Corporation $489.00 05/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 831121185
Principal investigator 1 Pharmacyclics LLC, an AbbVie Company $190.00 05/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) No dispute reported 06/30/2026 786502711
Principal investigator 1 Pharmacyclics LLC, an AbbVie Company $190.00 05/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) No dispute reported 06/30/2026 786502713
Principal investigator 1 Pharmacyclics LLC, an AbbVie Company $190.00 05/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) No dispute reported 06/30/2026 786502715
Principal investigator 1 Pharmacyclics LLC, an AbbVie Company $190.00 05/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) No dispute reported 06/30/2026 786502717
Principal investigator 1 Pharmacyclics LLC, an AbbVie Company $190.00 05/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) No dispute reported 06/30/2026 786502719
Principal investigator 1 Pharmacyclics LLC, an AbbVie Company $190.00 05/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) No dispute reported 06/30/2026 786502721
Principal investigator 1 Pharmacyclics LLC, an AbbVie Company $190.00 05/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) No dispute reported 06/30/2026 786502723
Principal investigator 1 BeiGene, Ltd. $18,800.00 04/26/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY-ARLINGTON SOUTH
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Intolerant of Prior Treatment with Ibrutinib No dispute reported 06/30/2026 843879679
Principal investigator 1 Incyte Corporation $1,147.78 04/22/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 831123197
Principal investigator 1 Incyte Corporation $489.00 04/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 831120819
Principal investigator 1 Incyte Corporation $850.00 04/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 831120825
Principal investigator 1 Incyte Corporation $105.00 04/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 831120831
Principal investigator 1 Incyte Corporation $489.00 04/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 831121009
Principal investigator 1 Pharmacyclics LLC, an AbbVie Company $190.00 04/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) No dispute reported 06/30/2026 786502697
Principal investigator 1 Pharmacyclics LLC, an AbbVie Company $190.00 04/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) No dispute reported 06/30/2026 786502699
Principal investigator 1 Pharmacyclics LLC, an AbbVie Company $190.00 04/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) No dispute reported 06/30/2026 786502701
Principal investigator 1 Pharmacyclics LLC, an AbbVie Company $190.00 04/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) No dispute reported 06/30/2026 786502703
Principal investigator 1 Pharmacyclics LLC, an AbbVie Company $190.00 04/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) No dispute reported 06/30/2026 786502705
Principal investigator 1 Pharmacyclics LLC, an AbbVie Company $190.00 04/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) No dispute reported 06/30/2026 786502707
Principal investigator 1 Pharmacyclics LLC, an AbbVie Company $638.00 04/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) No dispute reported 06/30/2026 786502709
Principal investigator 1 Seagen Inc. $956.00 04/15/2021 Non-covered Recipient Entity
Texas Oncology-Amarillo
A Dual-cohort, Open-label, Phase 2 Study of Brentuximab Vedotin and CHP (A+CHP) in the Frontline Treatment of Subjects With Peripheral T-cell Lymphoma (PTCL) With Less Than 10% CD30 Expression No dispute reported 06/30/2026 792678883
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $23,766.96 04/15/2021 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A GLOBAL, PROSPECTIVE, NON-INTERVENTIONAL, OBSERVATIONAL STUDY OF PRESENTATION, TREATMENT PATTERNS, AND OUTCOMES IN MULTIPLE MYELOMA PATIENTS - THE INSIGHT - MM STUDY No dispute reported 06/30/2026 816709473
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,586.40 04/15/2021 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A GLOBAL, PROSPECTIVE, NON-INTERVENTIONAL, OBSERVATIONAL STUDY OF PRESENTATION, TREATMENT PATTERNS, AND OUTCOMES IN MULTIPLE MYELOMA PATIENTS - THE INSIGHT - MM STUDY No dispute reported 06/30/2026 816709541
Principal investigator 1 BeiGene, Ltd. $1,125.00 04/05/2021 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A Single-Arm, Expanded Access Study of Zanubrutinib (BGB-3111) in Patients with B-cell Malignancies No dispute reported 06/30/2026 843874681
Principal investigator 1 Incyte Corporation $226.00 03/18/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 831120041
Principal investigator 1 Incyte Corporation $226.00 03/18/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 831120075
Principal investigator 1 Incyte Corporation $8,608.35 03/18/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 831120095
Principal investigator 1 Genentech, Inc. $8,075.00 03/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY SOUTHWEST FORT WORTH
CLL 1L FIT GV FCR BR No dispute reported 06/30/2026 836026585
Principal investigator 1 Incyte Corporation $489.00 03/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 831120299
Principal investigator 1 Incyte Corporation $105.00 03/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 831120305
Principal investigator 1 Pharmacyclics LLC, an AbbVie Company $190.00 03/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) No dispute reported 06/30/2026 786502681
Principal investigator 1 Pharmacyclics LLC, an AbbVie Company $190.00 03/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) No dispute reported 06/30/2026 786502683
Principal investigator 1 Pharmacyclics LLC, an AbbVie Company $190.00 03/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) No dispute reported 06/30/2026 786502685
Principal investigator 1 Pharmacyclics LLC, an AbbVie Company $190.00 03/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) No dispute reported 06/30/2026 786502687
Principal investigator 1 Pharmacyclics LLC, an AbbVie Company $190.00 03/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) No dispute reported 06/30/2026 786502689
Principal investigator 1 Pharmacyclics LLC, an AbbVie Company $190.00 03/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) No dispute reported 06/30/2026 786502691
Principal investigator 1 Pharmacyclics LLC, an AbbVie Company $190.00 03/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) No dispute reported 06/30/2026 786502693
Principal investigator 1 Pharmacyclics LLC, an AbbVie Company $190.00 03/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) No dispute reported 06/30/2026 786502695
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $6,867.80 03/09/2021 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A GLOBAL, PROSPECTIVE, NON-INTERVENTIONAL, OBSERVATIONAL STUDY OF PRESENTATION, TREATMENT PATTERNS, AND OUTCOMES IN MULTIPLE MYELOMA PATIENTS - THE INSIGHT - MM STUDY No dispute reported 06/30/2026 816696597
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,292.40 03/09/2021 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A GLOBAL, PROSPECTIVE, NON-INTERVENTIONAL, OBSERVATIONAL STUDY OF PRESENTATION, TREATMENT PATTERNS, AND OUTCOMES IN MULTIPLE MYELOMA PATIENTS - THE INSIGHT - MM STUDY No dispute reported 06/30/2026 816696607
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,004.70 03/09/2021 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A GLOBAL, PROSPECTIVE, NON-INTERVENTIONAL, OBSERVATIONAL STUDY OF PRESENTATION, TREATMENT PATTERNS, AND OUTCOMES IN MULTIPLE MYELOMA PATIENTS - THE INSIGHT - MM STUDY No dispute reported 06/30/2026 816696619
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,146.20 03/09/2021 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A GLOBAL, PROSPECTIVE, NON-INTERVENTIONAL, OBSERVATIONAL STUDY OF PRESENTATION, TREATMENT PATTERNS, AND OUTCOMES IN MULTIPLE MYELOMA PATIENTS - THE INSIGHT - MM STUDY No dispute reported 06/30/2026 816696687
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $429.24 03/09/2021 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A GLOBAL, PROSPECTIVE, NON-INTERVENTIONAL, OBSERVATIONAL STUDY OF PRESENTATION, TREATMENT PATTERNS, AND OUTCOMES IN MULTIPLE MYELOMA PATIENTS - THE INSIGHT - MM STUDY No dispute reported 06/30/2026 816696697
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,146.20 03/09/2021 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A GLOBAL, PROSPECTIVE, NON-INTERVENTIONAL, OBSERVATIONAL STUDY OF PRESENTATION, TREATMENT PATTERNS, AND OUTCOMES IN MULTIPLE MYELOMA PATIENTS - THE INSIGHT - MM STUDY No dispute reported 06/30/2026 816696705
Principal investigator 1 BeiGene, Ltd. $13,265.00 03/03/2021 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A Single-Arm, Expanded Access Study of Zanubrutinib (BGB-3111) in Patients with B-cell Malignancies No dispute reported 06/30/2026 843874655
Principal investigator 1 BeiGene, Ltd. $37,600.00 02/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY-ARLINGTON SOUTH
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Intolerant of Prior Treatment with Ibrutinib No dispute reported 06/30/2026 843877631
Principal investigator 1 Celgene Corporation $476.00 02/15/2021 Non-covered Recipient Entity
Texas Oncology
Connect MM- The Multiple Myeloma Disease Registry No dispute reported 06/30/2026 807115575
Principal investigator 1 Celgene Corporation $952.00 02/15/2021 Non-covered Recipient Entity
Texas Oncology
Connect MM- The Multiple Myeloma Disease Registry No dispute reported 06/30/2026 807115695
Principal investigator 1 Incyte Corporation $105.00 02/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 831120287
Principal investigator 1 Incyte Corporation $489.00 02/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 831120293
Principal investigator 1 Incyte Corporation $105.00 02/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 831120454
Principal investigator 1 Incyte Corporation $489.00 02/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 831120461
Principal investigator 1 Incyte Corporation $489.00 02/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 831120466
Principal investigator 1 Incyte Corporation $105.00 02/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 831120473
Principal investigator 1 Pharmacyclics LLC, an AbbVie Company $190.00 02/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) No dispute reported 06/30/2026 786502663
Principal investigator 1 Pharmacyclics LLC, an AbbVie Company $190.00 02/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) No dispute reported 06/30/2026 786502665
Principal investigator 1 Pharmacyclics LLC, an AbbVie Company $190.00 02/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) No dispute reported 06/30/2026 786502667
Principal investigator 1 Pharmacyclics LLC, an AbbVie Company $190.00 02/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) No dispute reported 06/30/2026 786502669
Principal investigator 1 Pharmacyclics LLC, an AbbVie Company $190.00 02/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) No dispute reported 06/30/2026 786502671
Principal investigator 1 Pharmacyclics LLC, an AbbVie Company $190.00 02/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) No dispute reported 06/30/2026 786502673
Principal investigator 1 Pharmacyclics LLC, an AbbVie Company $190.00 02/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) No dispute reported 06/30/2026 786502675
Principal investigator 1 Pharmacyclics LLC, an AbbVie Company $190.00 02/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) No dispute reported 06/30/2026 786502677
Principal investigator 1 Pharmacyclics LLC, an AbbVie Company $190.00 02/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) No dispute reported 06/30/2026 786502679
Principal investigator 2 Celgene Corporation $5,800.00 02/10/2021 Non-covered Recipient Entity
Texas Oncology
Connect MDS/AML No dispute reported 06/30/2026 837042045
Principal investigator 1 BeiGene, Ltd. $18,800.00 02/02/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY-ARLINGTON SOUTH
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Intolerant of Prior Treatment with Ibrutinib No dispute reported 06/30/2026 843879153
Principal investigator 1 Celgene Corporation $7,867.00 01/15/2021 Non-covered Recipient Entity
Texas Oncology
Connect MM- The Multiple Myeloma Disease Registry No dispute reported 06/30/2026 807115465
Principal investigator 1 Celgene Corporation $952.00 01/15/2021 Non-covered Recipient Entity
Texas Oncology
Connect MM- The Multiple Myeloma Disease Registry No dispute reported 06/30/2026 807115593
Principal investigator 1 Celgene Corporation $1,705.00 01/15/2021 Non-covered Recipient Entity
Texas Oncology
Connect MM- The Multiple Myeloma Disease Registry No dispute reported 06/30/2026 807115611
Principal investigator 1 Incyte Corporation $850.00 01/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 831120281
Principal investigator 1 Pharmacyclics LLC, an AbbVie Company $190.00 01/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) No dispute reported 06/30/2026 786502651
Principal investigator 1 Pharmacyclics LLC, an AbbVie Company $190.00 01/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) No dispute reported 06/30/2026 786502653
Principal investigator 1 Pharmacyclics LLC, an AbbVie Company $190.00 01/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) No dispute reported 06/30/2026 786502655
Principal investigator 1 Pharmacyclics LLC, an AbbVie Company $190.00 01/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) No dispute reported 06/30/2026 786502657
Principal investigator 1 Pharmacyclics LLC, an AbbVie Company $190.00 01/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) No dispute reported 06/30/2026 786502659
Principal investigator 1 Pharmacyclics LLC, an AbbVie Company $638.00 01/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) No dispute reported 06/30/2026 786502661